It is currently trading at $78.90 which is just over $73.05, the stock’s 50 day moving average and just a bit higher than the 200 day moving average of $53.57. The 50 day moving average was up $5.85 whereas the 200 day moving average was up $25.33 or +47.29%. Trading was light with 665K shares changing hands in the last trading session. Overall, volume was down 58.83% under the stocks normal daily volume.
Investors are more bearish lately if you take into consideration the uptick in short interest. The stock realized a rise in short interest of 6.89% as of May 31, 2017 from the last reporting period. Short shares grew from 9,243,681 to 9,880,836 over that timeframe. With short interest at 9,880,836 and short average daily volume at 944,134, the short-interest ratio is 10.5 and the short interest percentage is 0.11% as of May 31.
There has been some buying and selling insider activity on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) recently. Sr VP Laurie Keating bought 11,500 shares at an average price of $65.35 on Tue the 30th. The Sr VP now owns $751,525 of the stock as recorded in a recent Form 4 SEC filing. Akshay Vaishnaw, EVP, R&D disclosed the sale of 11,000 shares of (ALNY). The shares were sold on May 23rd for an average price of $75.00. Vaishnaw now owns $772,275 of the stock per the Form 4 SEC filing.
Michael Mason, VP, Finance and Treasurer disclosed the sale of 9,375 shares. The shares were purchased at an average price of $70.00. The VP, Finance and Treasurer now owns $0 of the stock according to the SEC filing.
These funds have also shifted positions in (ALNY). As of the end of the quarter Creative Planning had acquired a total of 38 shares growing its holdings by 3.8%. The value of the investment in Alnylam Pharmaceuticals, Inc. went from $52,000 to $83,000 a change of $31,000 for the reporting period. Rhenman & Partners Asset Management Ab reduced its position by shedding 49,810 shares a decrease of 38.3% from 03/31/2017 to 06/30/2017. Rhenman & Partners Asset Management Ab claims 80,190 shares worth $6,396,000. The total value of its holdings decreased 4.0%.
As of quarter end Bank Of Montreal /can/ had bought 446 shares growing its position 4.7%. The value of the company’s investment in Alnylam Pharmaceuticals, Inc. increased from $488,000 to $796,000 increasing 63.1% since the last quarter. As of the end of the quarter Capstone Asset Management Co had bought 350 shares growing its stake by 13.7%. The value of the total investment in Alnylam Pharmaceuticals, Inc. decreased from $241,000 to $232,000 a change of 3.7% quarter over quarter.
On October 7 the company was changed to a “Equal-weight” in a report from Morgan Stanley which was a cut from the previous “” rating. On October 7 the stock rating was downgraded to “Equal-weight” from “” by analysts at .
On October 6 the company was downgraded from “Outperform” to “Outperform” and a price target of $50.00 was set in a report issued by Leerink Swann. On October 6 the company was downgraded from “Overweight” to “Equal-weight” with a current price target of $50.00 in an announcement from Barclays.
On October 6 the company was downgraded to “Equal-weight” from “Equal-weight” by . Equity analyst Leerink Swann lowered the price target and downgraded the stock on October 6 changing the price objective from $107.00 to $50.00 and setting the rating at “Outperform” which had previously been “Outperform”.
The company is trading down by -0.13% since yesterday’s close of $79. As of the last earnings report the EPS was $-4.83 and is projected to be $-5.29 for the current year with 86,190,000 shares currently outstanding. Next quarter’s EPS is expected be $-1.30 with next year’s EPS projected to be $-5.02.
Alnylam Pharmaceuticals, Inc., launched on May 8, 2003, is a biopharmaceutical company. The Company is involved in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. Its lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs)..